Sana is a biotechnology company that develops ex vivo ... candidates for a wide array of therapeutic areas, throughout the Class Period, Defendants repeatedly touted Sana's financial wherewithal ...

Franklin Biotechnology Discovery Fund's Q1 2025 report covers market trends, key holdings, risks, and outlook—essential ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

CSU Channel Islands (CSUCI) will celebrate the graduating Class of 2025 during two ceremonies at 9 a.m. and 2 p.m. on Saturday, May 17, 2025.   Almost ...

Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology ...

If you suffered a loss in Sana Biotechnology, Inc. during the relevant ... NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket ...

Since 1971, the US has led the world in funding cancer research and developing new treatments that have driven down death ...

Natural products are among the most promising candidates for the development of new drugs. However, due to their structural complexity, they are often difficult to access.

THE LAWSUIT: A class action securities lawsuit was filed against Sana Biotechnology, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...

Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D., will present at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, held this week May 13-17, at the Ernest N.

Kesmalea Therapeutics, a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to ...